AN2 TherapeuticsANTX
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 36 institutions reported holding AN2 Therapeutics Inc. (ANTX) in their 13F filings, down 1 from Q2 2025. 2 opened new positions and 3 sold out. The largest holders were Almitas Capital LLC ($1.8M), Vanguard Group Inc. ($1.4M) and Pfizer Inc ($908K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- AN2 Therapeutics Inc.
- CUSIP
- 037326105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $18K |
| Exits | 3 | $88K |
All 13F filers, Q2 2025 → Q3 2025: 163,051 shares bought and 171,291 shares sold, net −8,240 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 36 holders
| Almitas Capital LLC | 0.42% | No change | 1,428,323 | $1.8M |
| Vanguard Group Inc. | 0.00% | Add +4.3% | 1,080,070 | $1.4M |
| Pfizer Inc | 0.21% | No change | 715,295 | $908K |
| Peapod Lane Capital LLC | 0.67% | Add +1.1% | 589,216 | $748K |
| Stonepine Capital Management, LLC | 0.58% | Add +3.6% | 563,913 | $716K |
| Bank of Nova Scotia | 0.00% | No change | 459,194 | $583K |
| Landscape Capital Management, L.L.C. | 0.04% | Reduce -7.9% | 456,463 | $580K |
| Bank of Montreal | 0.00% | No change | 422,077 | $536K |
| Renaissance Technologies | 0.00% | Reduce -3.3% | 385,597 | $490K |
| Bank of America Corp. | 0.00% | Reduce -0.1% | 385,310 | $489K |
| BlackRock, Inc. | 0.00% | Add +0.5% | 320,911 | $408K |
| Two Sigma Advisers, LP | 0.00% | Reduce -0.6% | 267,900 | $340K |
| Geode Capital Management, LLC | 0.00% | No change | 249,351 | $317K |
| Two Sigma Investments, LP | 0.00% | Reduce -6.3% | 223,337 | $284K |
| Morgan Stanley | 0.00% | Add +7.0% | 190,770 | $242K |
| State Street Corp. | 0.00% | No change | 87,002 | $110K |
| Rangeley Capital, LLC | 0.08% | No change | 65,000 | $83K |
| Squarepoint Ops LLC | 0.00% | Add +538.7% | 64,267 | $82K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 59,900 | $76K |
| UBS Group AG | 0.00% | Reduce -8.6% | 56,694 | $72K |
| Northern Trust Corp. | 0.00% | No change | 43,196 | $55K |
| Captrust Financial Advisors | 0.00% | No change | 40,000 | $51K |
| Citadel Advisors | 0.00% | Add +84.2% | 23,013 | $29K |
| Private Advisor Group, LLC | 0.00% | No change | 22,500 | $29K |
| XTX Topco Ltd | 0.00% | Reduce -28.8% | 18,541 | $24K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -16.6% | 14,281 | $18K |
| ACT Advisors, LLC. | 0.01% | New | 13,199 | $17K |
| Federated Hermes, Inc. | 0.00% | Reduce -2.9% | 11,882 | $15K |
| Qube Research & Technologies Ltd | 0.00% | No change | 10,184 | $13K |
| Highline Wealth Partners LLC | 0.00% | No change | 5,000 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -60.0% | 2,128 | $3K |
| Innovative Advisory Group, LLC | 0.00% | No change | 1,170 | $1K |
| FMR LLC | 0.00% | New | 1,000 | $1K |
| BNP Paribas Financial Markets | 0.00% | Reduce -2.9% | 303 | $385 |
| Osaic Holdings, Inc. | 0.00% | No change | 300 | $384 |
| SBI Securities Co., Ltd. | 0.00% | No change | 200 | $254 |
"% of holder's portfolio" is ANTX's weight in each manager's 13F, not the share of AN2 Therapeutics Inc. the manager owns.